Login
$SYRE
$99.07 -$4.93 (4.74%) Live

$SYRE SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is enrolling ahead o...

03 Nov 2026 10-Q
09 Oct 2026 SCHEDULE 13D/A
07 Oct 2026 8-K: Entry into a Material Definitive Agreement

Introductory. Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,117,648 shares (the “Firm Shares”) of its c...

06 Oct 2026 424B5
05 Oct 2026 424B5
02 Oct 2026 Form 4: King-Jones Heidy, See Remarks

Received 28,933 shares by exercise or conversion ($420K) · Sold 28,933 shares ($2.63M)

02 Oct 2026 Form 4: Turtle Cameron, Director

Sold 15,000 shares ($1.38M)

02 Oct 2026 Form 4: Burrows Scott L, Chief Financial Officer

Received 17,500 shares by exercise or conversion ($254K) · Sold 17,500 shares ($1.57M) · Received 7,500 shares by exercise or conversion ($109K) · 1 more

01 Oct 2026 144
01 Oct 2026 144
01 Oct 2026 SCHEDULE 13G
30 Sep 2026 144
08 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

03 Sep 2026 Form 4: King-Jones Heidy, See Remarks

Received 27,999 shares by exercise or conversion ($406K) · Sold 27,999 shares ($2.44M) · Received 400 shares by exercise or conversion ($5.8K) · 1 more

03 Sep 2026 Form 4: Burrows Scott L, Chief Financial Officer

Received 7,500 shares by exercise or conversion ($109K) · Sold 7,500 shares ($655K) · Sold 18,232 shares ($1.63M)

03 Sep 2026 Form 4: Turtle Cameron, Director

Sold 15,000 shares ($1.31M)

01 Sep 2026 144
25 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)

14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support